Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sorafenib (Primary) ; Paclitaxel
- Indications Adrenocortical carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms PAXO
- 23 Feb 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Nov 2008 New trial record.